This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development,…

MelanomaNon Small Cell Lung CancerSolid Tumor+2 more

~Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT03340506

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Background: All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewer out of 1 million people each year. Re…

Very Rare TumorsVery Rare CancersOther Solid Tumors+2 more

~Estimated

~$10 – $675

National Cancer Institute (NCI)NCT07489378

Observational

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy a…

Rare CancersCholangiocarcinomaCancer of Unknown Primary Site

~Estimated

~$10 – $6,250

TargetCancer FoundationNCT04504604